Literature DB >> 20405281

E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat.

Ian Kendall1, Helge A Slotten, Xavier Codony, Javier Burgueño, Peter J Pauwels, Jose M Vela, Kevin C F Fone.   

Abstract

RATIONALE AND
OBJECTIVES: In rats, 5-hydroxytryptamine(6) (5-HT(6)) receptor antagonists improve learning and memory, but the effects of agonists are poorly defined. This study investigated the effects of 5-HT(6) receptor agonists and antagonists on a rodent model of recognition memory.
METHODS: Selective 5-HT(6) receptor agonists and antagonists were administered either alone, after a scopolamine-induced impairment, or combined with sub-effective doses of the acetylcholinesterase inhibitor, donepezil, or the glutamate NMDA receptor antagonist, memantine, in a novel object discrimination paradigm in adult rats.
RESULTS: After a 4-h inter-trial delay to induce natural forgetting, vehicle-treated rats spent an equivalent time exploring novel and familiar objects during the choice trial. The 5-HT(6) receptor agonists, E-6801 (1.25-10 mg/kg i.p.) and EMD-386088 (5-10 mg/kg i.p.), and antagonists, SB-271046 and Ro 04-6790 (5 and 10 mg/kg), along with donepezil (0.1-3 mg/kg) and memantine (5-20 mg/kg) all produced significant and mostly dose-dependent increases in novel object exploration, indicative of memory enhancement. Furthermore, sub-effective doses of E-6801 (1 mg/kg) when co-administered with either SB-271046 (3 mg/kg), donepezil (0.1 mg/kg) or memantine (5 mg/kg), and EMD-386088 (2 mg/kg) co-administered with SB-271046 (3 mg/kg) also significantly enhanced object-recognition memory. Additionally, using a 1-min inter-trial delay, E-6801 (2.5 and 5 mg/kg) was as effective as donepezil (0.3 and 1 mg/kg) in reversing a scopolamine-induced (0.5 mg/kg) impairment in object recognition.
CONCLUSIONS: This is the first study to demonstrate that E-6801, a potent 5-HT(6) receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20405281     DOI: 10.1007/s00213-010-1854-3

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  77 in total

1.  Enhancement of place and object recognition memory in young adult and old rats by RS 67333, a partial agonist of 5-HT4 receptors.

Authors:  L Lamirault; H Simon
Journal:  Neuropharmacology       Date:  2001-12       Impact factor: 5.250

Review 2.  An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function.

Authors:  Kevin C F Fone
Journal:  Neuropharmacology       Date:  2008-07-04       Impact factor: 5.250

3.  A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data.

Authors:  A Ennaceur; J Delacour
Journal:  Behav Brain Res       Date:  1988-11-01       Impact factor: 3.332

4.  Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.

Authors:  R Kohen; M A Metcalf; N Khan; T Druck; K Huebner; J E Lachowicz; H Y Meltzer; D R Sibley; B L Roth; M W Hamblin
Journal:  J Neurochem       Date:  1996-01       Impact factor: 5.372

5.  An assessment of the effects of serotonin 6 (5-HT6) receptor antagonists in rodent models of learning.

Authors:  Mark D Lindner; Donald B Hodges; John B Hogan; Anitra F Orie; Jason A Corsa; Donna M Barten; Craig Polson; Barbara J Robertson; Valerie L Guss; Kevin W Gillman; John E Starrett; Valentin K Gribkoff
Journal:  J Pharmacol Exp Ther       Date:  2003-09-15       Impact factor: 4.030

6.  The serotonin1A receptor agonist 8-OHDPAT reverses delta 9-tetrahydrocannabinol-induced impairment of spatial memory and reduction of acetylcholine release in the dorsal hippocampus in rats.

Authors:  Keiichrio Inui; Nobuaki Egashira; Kenichi Mishima; Akiko Yano; Yoshiaki Matsumoto; Nobuyoshi Hasebe; Kohji Abe; Kazuhide Hayakawa; Tomoaki Ikeda; Katsunori Iwasaki; Michihiro Fujiwara
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 7.  Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders.

Authors:  Kevin C F Fone; M Veronica Porkess
Journal:  Neurosci Biobehav Rev       Date:  2008-03-18       Impact factor: 8.989

8.  High throughput screening technologies for direct cyclic AMP measurement.

Authors:  Daniela Gabriel; Magali Vernier; Martin J Pfeifer; Boris Dasen; Laurent Tenaillon; Rochdi Bouhelal
Journal:  Assay Drug Dev Technol       Date:  2003-04       Impact factor: 1.738

9.  A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation.

Authors:  M Ruat; E Traiffort; J M Arrang; J Tardivel-Lacombe; J Diaz; R Leurs; J C Schwartz
Journal:  Biochem Biophys Res Commun       Date:  1993-05-28       Impact factor: 3.575

Review 10.  Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse.

Authors:  Chris G Parsons; Albrecht Stöffler; Wojciech Danysz
Journal:  Neuropharmacology       Date:  2007-08-10       Impact factor: 5.250

View more
  24 in total

1.  Serotonin revisited.

Authors:  Philip J Cowen; Irwin Lucki
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

Review 2.  Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models.

Authors:  L Lyon; L M Saksida; T J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2011-11-10       Impact factor: 4.530

3.  The 5-HT6 receptor agonist EMD 386088 produces antidepressant and anxiolytic effects in rats after intrahippocampal administration.

Authors:  Agnieszka Nikiforuk; Tomasz Kos; Anna Wesołowska
Journal:  Psychopharmacology (Berl)       Date:  2011-04-16       Impact factor: 4.530

Review 4.  Alzheimer's disease and age-related memory decline (preclinical).

Authors:  Alvin V Terry; Patrick M Callahan; Brandon Hall; Scott J Webster
Journal:  Pharmacol Biochem Behav       Date:  2011-02-24       Impact factor: 3.533

5.  Donepezil, an acetylcholinesterase inhibitor, attenuates nicotine self-administration and reinstatement of nicotine seeking in rats.

Authors:  Blake A Kimmey; Laura E Rupprecht; Matthew R Hayes; Heath D Schmidt
Journal:  Addict Biol       Date:  2012-12-12       Impact factor: 4.280

6.  The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in rats.

Authors:  Eric G Mohler; Phillip M Baker; Kimberly S Gannon; Simon S Jones; Sharon Shacham; John A Sweeney; Michael E Ragozzino
Journal:  Psychopharmacology (Berl)       Date:  2011-10-12       Impact factor: 4.530

Review 7.  An overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels.

Authors:  Xiaoling Zhou; Yifei Li; Xiaozhe Shi; Chun Ma
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

8.  Antidepressant-like activity of EMD 386088, a 5-HT6 receptor partial agonist, following systemic acute and chronic administration to rats.

Authors:  Magdalena Jastrzębska-Więsek; Agata Siwek; Anna Partyka; Bernadeta Szewczyk; Magdalena Sowa-Kućma; Anna Wasik; Marcin Kołaczkowski; Anna Wesołowska
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-06-16       Impact factor: 3.000

Review 9.  Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status.

Authors:  Maria J Ramirez; Mitchell K P Lai; Rosa M Tordera; Paul T Francis
Journal:  Drugs       Date:  2014-05       Impact factor: 9.546

Review 10.  The role of serotonin in memory: interactions with neurotransmitters and downstream signaling.

Authors:  Mohammad Seyedabadi; Gohar Fakhfouri; Vahid Ramezani; Shahram Ejtemaei Mehr; Reza Rahimian
Journal:  Exp Brain Res       Date:  2014-01-16       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.